Evolution over 10 years of costs and benefits of familial hypercholesterolaemia service in Southampton, Hampshire, Isle of Wight and Portsmouth area: National.

Slides:

Advertisements

Similar presentations

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

Advertisements

MACE rate among CAD severity groups (total 0

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Receiver operating curves (ROC) of the Framingham and QRISK2 risk factor models for predicting 10-year risk of cardiovascular disease with and without.

Flow chart of the used methodology adapted from Moher et al

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Percentage of National Health Service (NHS) expenditure on cardiovascular disease by care setting, England 2012/2013. Percentage of National Health Service.

Masashi Maeda et al. Heart Asia 2013;5:7-14

Modelled changes in gastrointestinal endoscopy activity 2013/2014 to 2019/ WW, 2-week wait; BCSP, Bowel Cancer Screening Programme; FIT, faecal.

(A) Image of a stent that was damaged withdrawing it back into a Guideliner V2 after failing to cross the lesion. (A) Image of a stent that was damaged.

The procedural journey for our cohort of patients with persistent atrial fibrillation. The procedural journey for our cohort of patients with persistent.

HOMA calculations where glucose is mmol/L and insulin is mU/L

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

Metaregression showing the relationship between mortality and antiplatelet strategy. Metaregression showing the relationship between mortality and antiplatelet.

(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.

Comparison of CMR and echocardiography in aortic regurgitation.

Correlation of change in H2 concentration (△H2) haemodynamics or laboratory parameters. Correlation of change in H2 concentration (△H2) haemodynamics or.

Changes in smoking behaviour over time.

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

The proportion of patients confronted with a cardiovascular risk factor (CVRF) they were previously unaware of, referring to the instrument based tests.

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

Toray microarray analysis of the four groups of patients (A) and in patients with calcium score >100 (B). Toray microarray analysis of the four groups.

Absolute ST segment elevation at the beginning of the primary percutaneous coronary intervention procedure (A), after guidewire passage (B), after thrombus.

Receiver operating characteristics curve of N-terminal pro-atrial natriuretic peptide plasma levels (dark line) and brain natriuretic peptide (dashed line)

Baseline plasma levels of cathepsin D (A), cathepsin L (B) and cystatin B (C) are increased in individuals who developed coronary events (CEs) during follow-up.

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

Percentage of endometrial ablation procedures using balloon or microwave ablation procedures—National Institute for Health and Care Excellence guidance.

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

UK paediatric cardiac surgery mortality rate by year for all cases and total number of procedures performed between 2000 and 2009/2010. UK paediatric cardiac.

Associations between presence of tachycardia at time of admission (heart rate ≥120/min) and the primary composite outcome of death or cardiovascular rehospitalisation,

(A) Quantitative plaque analysis of the RCA

Associations between atmospheric chemistry transport model pollution concentrations at lags 0, 1 and 2 and myocardial infarction (% change in risk per.

Cost of healthcare and sick leave before and after heart valve surgery (€). Cost of healthcare and sick leave before and after heart valve surgery (€).

Flow chart showing reinterventions by type in patients with anomalous origin of coronary artery from the pulmonary artery patients, divided into early.

Kaplan-Meier curve of cumulative percentage of cardiac mortality by peak flow rate category (adjusted HRs (95% CI) compared with ≥550 L/min: (

Left atrium maximum volume (LAmax) for echocardiography and cardiovascular magnetic resonance (CMR). Left atrium maximum volume (LAmax) for echocardiography.

Different behaviours between group 1 and group 2 patients of the mean and SD of Δ for low frequency (LF), high frequency (HF) and total power (TP) calculated.

Scatter plot of estimated joint density of incremental costs and incremental effects (quality-adjusted life years (EuroQol five-dimension questionnaire,

Kaplan–Meyer survival curve of 1313 patients following primary PCI

Potential effect of guidelines on ASCVD prevention in the CGPS*

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

The 6MWT results showing improvement from baseline at 1, 6 and 12 months in patients receiving an implant (mean±SE of mean). The 6MWT results showing improvement.

Analysis of receiver operating characteristic of fetuin-A.

(A) The types of costs that were included in the analysis, and (B) the types of costs that were not included (modified from Torrance et al27). *Indicates.

Average left ventricular ejection fraction (LVEF) values during the 1 year of observation in patients with preserved systolic function (LVEF >40%) and.

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Expected value of perfect implementation: population net health benefit and maximum justifiable investment if all patients who were eligible received beta.

Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.

Year-wise trends in MRRUF

Relation between institutional volume and MRRUF

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

The fractional flow reserve (FFR) values according to increasing risks of the Multifunction CardioGram (MCG) scores. The fractional flow reserve (FFR)

Deterministic univariate sensitivity analyses (BAV, balloon aortic valvuloplasty; ICU, intensive care unit; MM, medical management; QALY, quality-adjusted.

Percentage of percutaneous coronary interventions using drug-eluting stents in a National Health Service setting in England—National Institute for Health.

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Risk for cardiovascular disease and all-cause death according to RHR: (A) as categorical variable (HR≥75 bpm vs HR

Unadjusted event-free survival (days alive and out-of-hospital) of participants with and without MCI in (A) overall cohort, (B) standard management cohort.

Calculating the overall accuracy in different samples using the V-plot

Disease severity and classification agreement between methods: schematic representation of the principle that classification agreement between two methods.

Percentage of individuals aged 16 and over taking cardiovascular-related prescriptions, by sex, England 2012–2013. Percentage of individuals aged 16 and.

Countries and areas of the Western Pacific region included within the scope of this study. Taiwan does not have WHO Member State status but is within this.

The QT interval responses to different pacing rates in a patient in group I. The pacing rate was decreased from 110 to 50 beats/min and the QT interval.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Kaplan-Meier plot for the prespecified primary endpoint (CARE-HF (A) and the secondary composite endpoint (all-cause mortality and new onset heart failure.

Prevalence of regular non-steroidal anti-inflammatory drug (NSAID) use by age and race/ethnicity. Prevalence of regular non-steroidal anti-inflammatory.

Determinants of moderate Cardiovascular Health Index Score (achieving three or more risk factor targets), stratified by region conventions as in figure.

Proportions of the social isolation—AMI and stroke excess risk mediated by biological, behavioural, socioeconomic and health-related factors. Proportions.

Comparison of heart failure admissions rates per annum (recorded hospital admissions/ population at risk) in western developed countries 1978 to.

Presentation transcript:

Evolution over 10 years of costs and benefits of familial hypercholesterolaemia service in Southampton, Hampshire, Isle of Wight and Portsmouth area: National Institute for Health and Care Excellence with atorvastatin off patent compared to three alternativ... Evolution over 10 years of costs and benefits of familial hypercholesterolaemia service in Southampton, Hampshire, Isle of Wight and Portsmouth area: National Institute for Health and Care Excellence with atorvastatin off patent compared to three alternative models of delivery. Robert Pears et al. Open Heart 2014;1:e000015 ©2014 by British Cardiovascular Society